BondsMedium•6 November 2026•
1 min read
S&P Global Ratings Revises Boston Scientific Outlook to Negative
Key Facts
1S&P Global Ratings revised its outlook on Boston Scientific Corp. to negative.
S&P Global Ratings revised its outlook on Boston Scientific Corp. to negative. Investing.com reported that the shift signals a potential credit rating downgrade in the medium term following the company's Q3 financial results.
BSX closed at $44.64 on November 5, 2026, after reaching a day high of $46.85 and a low of $43.9 during the session. The revision follows concerns regarding acquisition financing and operational risks, which may lead to higher borrowing costs for the corporation.